Navigating Recent Advances in the
Treatment of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC):
Expert Perspectives on Immunotherapy in an Evolving Treatment
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the webinar held November 11, 2020
This activity is valid from February 1, 2021 to March 1, 2023
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Merck Sharp & Dohme Corp.
Head and neck squamous cell carcinoma (HNSCC) represents a
heterogeneous group of tumors that originate in the lip/oral cavity,
hypopharynx, oropharynx, nasopharynx, and larynx. An estimated
48,330 new cases are diagnosed annually in the US, and 9,570 people
die of the disease. HNSCC historically has been associated with
tobacco and alcohol use; however, during the past decade, infection
with HPV has been implicated in the pathogenesis of a growing subset
of HNSCCs. Despite advances and innovations in past years, the
prognosis for metastatic disease remains poor. Fortunately for
patients with metastatic HNSCC, new immunotherapeutic options, which
have shown improved efficacy and safety, have recently become
available to give clinicians and managed care professionals more
options when managing a population of metastatic HNSCC patients.
Upon completion of this
activity, participants will be able to:
Examine recent clinical data on
immunotherapies in the first-line treatment of metastatic head
and neck squamous cell carcinoma (HNSCC)
Integrate immune checkpoint
inhibitors into the management of patients with
Identify metastatic HNSCC patients
who would potentially benefit from the use of checkpoint
Analyze strategies to optimally
sequence immunotherapy regimens in metastatic HNSCC
Explore strategies to mitigate
immune-related adverse events in patients with HNSCC receiving
immunotherapy or multimodal combinations with immunotherapy
||Ezra Cohen, MD, FRCPSC,
Professor, Division of Hematology/Oncology, Department
UC San Diego Health
Co-director, San Diego Center for Precision
Co-director, Head and Neck Cancer Center of Excellence
UC San Diego Moores Cancer Center
serves as a consultant for ALX Oncology, Ascendis,
Bayer, Bioline Rx, BMS, Debio, Dynavax, MSD, Merck,
Regeneron, and Sanofi. His presentation has been peer
reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue